Positive and negative modulation of nicotinic receptors.
Nicotinic acetylcholine receptors (AChRs) are one of the best characterized ion channels from the Cys-loop receptor superfamily. The study of acetylcholine binding proteins and prokaryotic ion channels from different species has been paramount for the understanding of the structure-function relationship of the Cys-loop receptor superfamily. AChR function can be modulated by different ligand types. The neurotransmitter ACh and other agonists trigger conformational changes in the receptor, finally opening the intrinsic cation channel. The so-called gating process couples ligand binding, located at the extracellular portion, to the opening of the ion channel, located at the transmembrane region. After agonist activation, in the prolonged presence of agonists, the AChR becomes desensitized. Competitive antagonists overlap the agonist-binding sites inhibiting the pharmacological action of agonists. Positive allosteric modulators (PAMs) do not bind to the orthostetic binding sites but allosterically enhance the activity elicited by agonists by increasing the gating process (type I) and/or by decreasing desensitization (type II). Instead, negative allosteric modulators (NAMs) produce the opposite effects. Interestingly, this negative effect is similar to that found for another class of allosteric drugs, that is, noncompetitive antagonists (NCAs). However, the main difference between both categories of drugs is based on their distinct binding site locations. Although both NAMs and NCAs do not bind to the agonist sites, NACs bind to sites located in the ion channel, whereas NAMs bind to nonluminal sites. However, this classification is less clear for NAMs interacting at the extracellular-transmembrane interface where the ion channel mouth might be involved. Interestingly, PAMs and NAMs might be developed as potential medications for the treatment of several diseases involving AChRs, including dementia-, skin-, and immunological-related diseases, drug addiction, and cancer. More exciting is the potential combination of specific agonists with specific PAMs. However, we are still in the beginning of understanding how these compounds act and how these drugs can be used therapeutically.
Department of Pharmaceutical Sciences, Midwestern University, Glendale, AZ, USA.
Hugo R
HR
Arias
D000109:Acetylcholine / Q000737:chemistry / Q000502:physiology; D000494:Allosteric Regulation; D000495:Allosteric Site / Q000235:genetics; D000818:Animals; D018680:Cholinergic Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D018360:Crystallography, X-Ray; D006801:Humans; D015640:Ion Channel Gating / Q000187:drug effects; D051379:Mice; D018722:Nicotinic Agonists / Q000494:pharmacology* / Q000627:therapeutic use; D017434:Protein Structure, Tertiary; D011978:Receptors, Nicotinic / Q000737:chemistry* / Q000502:physiology*; D013329:Structure-Activity Relationship
D018680:Cholinergic Antagonists; D018722:Nicotinic Agonists; D011978:Receptors, Nicotinic; D000109:Acetylcholine